RISS 검색 - 국내학술지논문 상세보기

다국어 초록 (Multilingual Abstract)

Objective: Pharmacotherapy including mood stabilizers and antipsychotics are frequently used in bipolar disorder (BD); however, the lack of consensus regarding the definition of polypharmacy hinders conducting comparative studies across different settings and countries. Research on Asian Prescription Pattern (REAP) is the largest and the longest lasting international collaborative research in psychiatry in Asia. The objective of REAP BD was to investigate the prescription patterns of psychotropic medications across Asian countries. The rates of polypharmacy and psychotropic drug load were also analyzed. Methods: The data collection was web-based. Prescription patterns were categorized as (1) mood stabilizer monotherapy: one mood stabilizer; (2) antipsychotic monotherapy: one antipsychotic; (3) simple polypharmacy: one mood stabilizer and one antipsychotic; and (4) complex polypharmacy: ≥ 2 mood stabilizers or/and antipsychotics. The psychotropic drug load in each patient was calculated using the defined daily dose method. Results: Among 2003 patients with BD (52.1% female, 42.4 years) from 12 countries, 1,619 (80.8%) patients received mood stabilizers, 1,644 (82.14%) received antipsychotics, and 424 (21.2%) received antidepressants, with 14.7% mood stabilizer monotherapy, 13.4% antipsychotic monotherapy, 48.9% simple polypharmacy, 20.3% complex polypharmacy, and 2.6% other therapy. The average psychotropic drug load was 2.05 ± 1.40. Results varied widely between countries. Conclusion: Over 70% of psychotropic regimens involved polypharmacy, which accords with the high prevalence of polypharmacy in BD under a permissive criterion (2 or more core psychotropic drugs) worldwide. Notably, ≥ 80% of our sample received antipsychotics, which may indicate an increasing trend in antipsychotic use for BD treatment.

번역하기

목차 (Table of Contents)

INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES

INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES

참고문헌 (Reference)

1 World Health Organization, "WHO Collaborating centre for drug statistics and methodology" World Health Organization

2 Muneer A, "The treatment of adult bipolar disorder with aripiprazole : a systematic review" 8 : e562-, 2016

3 Jaracz J, "The pattern of pharmacological treatment of bipolar patients discharged from psychiatric units in Poland" 70 : 694-698, 2018

4 Grunze H, "The World Federation of Societies of Biological Psychiatry(WFSBP)guidelines for the biological treatment of bipolar disorders : update 2012 on the long-term treatment of bipolar disorder" 14 : 154-219, 2013

5 Fountoulakis KN, "The International College of Neuro-Psychopharmacology(CINP)treatment guidelines for bipolar disorder in adults(CINP-BD-2017), part 3 : the clinical guidelines" 20 : 180-195, 2017

6 Lähteenvuo M, "Real-world effectiveness of pharmacologic treatments for the prevention of rehospitalization in a Finnish nationwide cohort of patients with bipolar disorder" 75 : 347-355, 2018

7 Fornaro M, "Prevalence and clinical features associated with bipolar disorder polypharmacy : a systematic review" 12 : 719-735, 2016

8 Hayes J, "Prescribing trends in bipolar disorder : cohort study in the United Kingdom THIN primary care database 1995-2009" 6 : e28725-, 2011

9 Lehman AF, "Practice guideline for the treatment of patients with schizophrenia, second edition" 161 (161): 1-56, 2004

10 Yang SY, "Polypharmacy and psychotropic drug loading in patients with schizophrenia in Asian countries : fourth survey of Research on Asian Prescription Patterns on antipsychotics" 72 : 572-579, 2018